Biologically Active Small Molecules

An inhibitor of ALK with an IC₅₀ value of 200 pM in enzymatic assays inhibits ALK in cells (IC₅₀ = 25 nM) and in vivo, producing tumor regression in a rat xenograft model.

An inhibitor of ALK with an IC₅₀ value of 200 pM in enzymatic assays inhibits ALK in cells (IC₅₀ = 25 nM) and in vivo, producing tumor regression in a rat xenograft model.

An inhibitor of ALK with an IC₅₀ value of 200 pM in enzymatic assays inhibits ALK in cells (IC₅₀ = 25 nM) and in vivo, producing tumor regression in a rat xenograft model.

An inhibitor of ALK with an IC₅₀ value of 200 pM in enzymatic assays inhibits ALK in cells (IC₅₀ = 25 nM) and in vivo, producing tumor regression in a rat xenograft model.

An inhibitor of HMG-CoA reductase.

An inhibitor of HMG-CoA reductase.

An inhibitor of HMG-CoA reductase.

An irreversible inhibitor of fatty acid synthase (FAS) causes cytoxicity and apoptosis in human cancer cell lines causes weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.

An irreversible inhibitor of fatty acid synthase (FAS) causes cytoxicity and apoptosis in human cancer cell lines causes weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.

An irreversible inhibitor of fatty acid synthase (FAS) causes cytoxicity and apoptosis in human cancer cell lines causes weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.

The fibrate class of hypolipidemic drugs such as clofibrate and fenofibrate elicit their effects by binding to and activating peroxisome proliferator-activated receptor &alpha (PPAR&alpha). Cetaben is a unique, PPAR&alpha-independent peroxisome

The fibrate class of hypolipidemic drugs such as clofibrate and fenofibrate elicit their effects by binding to and activating peroxisome proliferator-activated receptor &alpha (PPAR&alpha). Cetaben is a unique, PPAR&alpha-independent peroxisome